nodes	percent_of_prediction	percent_of_DWPC	metapath
Imatinib—PDGFRB—prostate cancer	0.126	0.395	CbGaD
Imatinib—SLC22A1—prostate cancer	0.0716	0.224	CbGaD
Imatinib—CYP3A5—prostate cancer	0.0578	0.181	CbGaD
Imatinib—CYP2C19—prostate cancer	0.0393	0.123	CbGaD
Imatinib—SLC47A1—Mitoxantrone—prostate cancer	0.0306	0.0829	CbGbCtD
Imatinib—ORM1—Abiraterone—prostate cancer	0.0266	0.0722	CbGbCtD
Imatinib—CYP3A4—prostate cancer	0.025	0.0782	CbGaD
Imatinib—ABCG2—Cabazitaxel—prostate cancer	0.012	0.0326	CbGbCtD
Imatinib—ABCG2—Estrone—prostate cancer	0.0118	0.0318	CbGbCtD
Imatinib—ALB—Abiraterone—prostate cancer	0.0112	0.0304	CbGbCtD
Imatinib—SLC22A2—Estradiol—prostate cancer	0.00915	0.0248	CbGbCtD
Imatinib—CYP3A5—Flutamide—prostate cancer	0.00901	0.0244	CbGbCtD
Imatinib—CYP2C19—Nilutamide—prostate cancer	0.00877	0.0238	CbGbCtD
Imatinib—CYP2C19—Bicalutamide—prostate cancer	0.00877	0.0238	CbGbCtD
Imatinib—ALB—Estrone—prostate cancer	0.0081	0.022	CbGbCtD
Imatinib—CYP3A4—Estradiol valerate/Dienogest—prostate cancer	0.00807	0.0219	CbGbCtD
Imatinib—SLC22A1—Estradiol—prostate cancer	0.00795	0.0215	CbGbCtD
Imatinib—ABCG2—Conjugated Estrogens—prostate cancer	0.00769	0.0208	CbGbCtD
Imatinib—CYP2C9—Nilutamide—prostate cancer	0.00729	0.0197	CbGbCtD
Imatinib—CYP2C9—Bicalutamide—prostate cancer	0.00729	0.0197	CbGbCtD
Imatinib—CYP2C19—Flutamide—prostate cancer	0.00727	0.0197	CbGbCtD
Imatinib—ABCG2—Mitoxantrone—prostate cancer	0.00699	0.0189	CbGbCtD
Imatinib—ABCG2—Estradiol—prostate cancer	0.00675	0.0183	CbGbCtD
Imatinib—CYP1A2—Flutamide—prostate cancer	0.00671	0.0182	CbGbCtD
Imatinib—CYP2D6—Bicalutamide—prostate cancer	0.00667	0.0181	CbGbCtD
Imatinib—CYP3A5—Cabazitaxel—prostate cancer	0.00666	0.0181	CbGbCtD
Imatinib—ABCB1—Estramustine—prostate cancer	0.00658	0.0178	CbGbCtD
Imatinib—CYP3A5—Estrone—prostate cancer	0.00651	0.0176	CbGbCtD
Imatinib—CYP2D6—Abiraterone—prostate cancer	0.00553	0.015	CbGbCtD
Imatinib—CYP3A7-CYP3A51P—Estradiol—prostate cancer	0.00499	0.0135	CbGbCtD
Imatinib—CYP3A7—Estradiol—prostate cancer	0.00499	0.0135	CbGbCtD
Imatinib—CYP1A2—Estrone—prostate cancer	0.00485	0.0131	CbGbCtD
Imatinib—ALB—Estradiol—prostate cancer	0.00466	0.0126	CbGbCtD
Imatinib—ABCG2—Etoposide—prostate cancer	0.00441	0.0119	CbGbCtD
Imatinib—CYP2C9—Estrone—prostate cancer	0.00437	0.0118	CbGbCtD
Imatinib—ABCB1—Cabazitaxel—prostate cancer	0.00434	0.0117	CbGbCtD
Imatinib—CYP3A4—Bicalutamide—prostate cancer	0.00424	0.0115	CbGbCtD
Imatinib—ABCB1—Estrone—prostate cancer	0.00424	0.0115	CbGbCtD
Imatinib—PTGS1—Etoposide—prostate cancer	0.00407	0.011	CbGbCtD
Imatinib—ABCG2—Docetaxel—prostate cancer	0.00403	0.0109	CbGbCtD
Imatinib—ALB—Prednisone—prostate cancer	0.004	0.0108	CbGbCtD
Imatinib—CYP3A4—Estramustine—prostate cancer	0.00394	0.0107	CbGbCtD
Imatinib—ABCB1—Ethinyl Estradiol—prostate cancer	0.00378	0.0102	CbGbCtD
Imatinib—CYP3A5—Estradiol—prostate cancer	0.00374	0.0101	CbGbCtD
Imatinib—CYP3A4—Flutamide—prostate cancer	0.00351	0.00952	CbGbCtD
Imatinib—CYP3A4—Abiraterone—prostate cancer	0.00351	0.00952	CbGbCtD
Imatinib—CYP2C9—Capecitabine—prostate cancer	0.00331	0.00897	CbGbCtD
Imatinib—CYP1A2—Conjugated Estrogens—prostate cancer	0.00317	0.00859	CbGbCtD
Imatinib—CYP2C19—Estradiol—prostate cancer	0.00302	0.00817	CbGbCtD
Imatinib—ABCG2—Doxorubicin—prostate cancer	0.00301	0.00814	CbGbCtD
Imatinib—CYP3A7—Docetaxel—prostate cancer	0.00298	0.00807	CbGbCtD
Imatinib—CYP3A7-CYP3A51P—Docetaxel—prostate cancer	0.00298	0.00807	CbGbCtD
Imatinib—CYP1A2—Estradiol—prostate cancer	0.00278	0.00754	CbGbCtD
Imatinib—ABCB1—Conjugated Estrogens—prostate cancer	0.00277	0.00751	CbGbCtD
Imatinib—PDGFRA—penis—prostate cancer	0.0027	0.0508	CbGeAlD
Imatinib—CYP3A4—Cabazitaxel—prostate cancer	0.0026	0.00704	CbGbCtD
Imatinib—CYP2C19—Prednisone—prostate cancer	0.0026	0.00703	CbGbCtD
Imatinib—CYP3A4—Estrone—prostate cancer	0.00254	0.00688	CbGbCtD
Imatinib—ABCB1—Mitoxantrone—prostate cancer	0.00252	0.00683	CbGbCtD
Imatinib—CYP2C9—Estradiol—prostate cancer	0.00251	0.0068	CbGbCtD
Imatinib—CYP3A5—Etoposide—prostate cancer	0.00244	0.00662	CbGbCtD
Imatinib—ABCB1—Estradiol—prostate cancer	0.00243	0.00659	CbGbCtD
Imatinib—CYP3A4—Ethinyl Estradiol—prostate cancer	0.00226	0.00613	CbGbCtD
Imatinib—CYP3A5—Docetaxel—prostate cancer	0.00224	0.00605	CbGbCtD
Imatinib—ABCB1—Prednisone—prostate cancer	0.00209	0.00567	CbGbCtD
Imatinib—CYP1A2—Etoposide—prostate cancer	0.00182	0.00492	CbGbCtD
Imatinib—CYP3A4—Conjugated Estrogens—prostate cancer	0.00166	0.0045	CbGbCtD
Imatinib—ABCB1—Etoposide—prostate cancer	0.00159	0.00431	CbGbCtD
Imatinib—ABCA3—prostate gland—prostate cancer	0.00155	0.0291	CbGeAlD
Imatinib—CYP3A4—Mitoxantrone—prostate cancer	0.00151	0.00409	CbGbCtD
Imatinib—CYP3A4—Estradiol—prostate cancer	0.00146	0.00395	CbGbCtD
Imatinib—ABCB1—Docetaxel—prostate cancer	0.00145	0.00394	CbGbCtD
Imatinib—DDR1—prostate gland—prostate cancer	0.00143	0.0268	CbGeAlD
Imatinib—Ponatinib—FGFR4—prostate cancer	0.00135	0.347	CrCbGaD
Imatinib—ABCA3—seminal vesicle—prostate cancer	0.00131	0.0246	CbGeAlD
Imatinib—CYP3A4—Prednisone—prostate cancer	0.00125	0.0034	CbGbCtD
Imatinib—DDR1—seminal vesicle—prostate cancer	0.00121	0.0227	CbGeAlD
Imatinib—ABCB1—Doxorubicin—prostate cancer	0.00108	0.00294	CbGbCtD
Imatinib—ABCA3—urethra—prostate cancer	0.00104	0.0195	CbGeAlD
Imatinib—CYP2D6—Doxorubicin—prostate cancer	0.00102	0.00277	CbGbCtD
Imatinib—DDR1—urethra—prostate cancer	0.000957	0.018	CbGeAlD
Imatinib—CYP3A4—Etoposide—prostate cancer	0.000953	0.00258	CbGbCtD
Imatinib—ABL2—prostate gland—prostate cancer	0.000932	0.0175	CbGeAlD
Imatinib—CYP2C19—urine—prostate cancer	0.000931	0.0175	CbGeAlD
Imatinib—PIP4K2C—prostate gland—prostate cancer	0.000882	0.0166	CbGeAlD
Imatinib—CYP3A4—Docetaxel—prostate cancer	0.000872	0.00236	CbGbCtD
Imatinib—NTRK1—testis—prostate cancer	0.000863	0.0162	CbGeAlD
Imatinib—Nilotinib—EPHB2—prostate cancer	0.000849	0.218	CrCbGaD
Imatinib—CA3—prostate gland—prostate cancer	0.000842	0.0158	CbGeAlD
Imatinib—LCK—prostate gland—prostate cancer	0.000783	0.0147	CbGeAlD
Imatinib—CA14—prostate gland—prostate cancer	0.000765	0.0144	CbGeAlD
Imatinib—CYP1A2—urine—prostate cancer	0.00076	0.0143	CbGeAlD
Imatinib—PIP4K2C—seminal vesicle—prostate cancer	0.000746	0.014	CbGeAlD
Imatinib—CYP2C9—urine—prostate cancer	0.000722	0.0135	CbGeAlD
Imatinib—HIPK4—testis—prostate cancer	0.00069	0.0129	CbGeAlD
Imatinib—ABCA3—testis—prostate cancer	0.000682	0.0128	CbGeAlD
Imatinib—CYP3A4—Doxorubicin—prostate cancer	0.00065	0.00176	CbGbCtD
Imatinib—NQO2—prostate gland—prostate cancer	0.000648	0.0122	CbGeAlD
Imatinib—CA14—seminal vesicle—prostate cancer	0.000647	0.0121	CbGeAlD
Imatinib—PDGFRA—prostate gland—prostate cancer	0.000646	0.0121	CbGeAlD
Imatinib—DDR1—testis—prostate cancer	0.000629	0.0118	CbGeAlD
Imatinib—CA7—renal system—prostate cancer	0.000626	0.0117	CbGeAlD
Imatinib—PIP4K2C—urethra—prostate cancer	0.00059	0.0111	CbGeAlD
Imatinib—CSF1R—prostate gland—prostate cancer	0.000569	0.0107	CbGeAlD
Imatinib—CYP3A4—urine—prostate cancer	0.00055	0.0103	CbGeAlD
Imatinib—NQO2—seminal vesicle—prostate cancer	0.000548	0.0103	CbGeAlD
Imatinib—CYP2D6—urine—prostate cancer	0.000541	0.0102	CbGeAlD
Imatinib—LCK—urethra—prostate cancer	0.000524	0.00984	CbGeAlD
Imatinib—SLC47A1—prostate gland—prostate cancer	0.000519	0.00975	CbGeAlD
Imatinib—KIT—prostate gland—prostate cancer	0.000516	0.0097	CbGeAlD
Imatinib—PDGFRB—prostate gland—prostate cancer	0.000504	0.00947	CbGeAlD
Imatinib—ABCA3—lymph node—prostate cancer	0.000494	0.00928	CbGeAlD
Imatinib—Ponatinib—FGFR2—prostate cancer	0.000493	0.126	CrCbGaD
Imatinib—CSF1R—seminal vesicle—prostate cancer	0.000481	0.00903	CbGeAlD
Imatinib—ORM1—prostate gland—prostate cancer	0.000473	0.00888	CbGeAlD
Imatinib—DDR1—lymph node—prostate cancer	0.000456	0.00857	CbGeAlD
Imatinib—PIP4K2C—bone marrow—prostate cancer	0.000454	0.00853	CbGeAlD
Imatinib—ABL1—prostate gland—prostate cancer	0.00045	0.00844	CbGeAlD
Imatinib—NQO2—renal system—prostate cancer	0.000441	0.00829	CbGeAlD
Imatinib—PDGFRA—renal system—prostate cancer	0.00044	0.00827	CbGeAlD
Imatinib—SLC47A1—seminal vesicle—prostate cancer	0.000439	0.00825	CbGeAlD
Imatinib—KIT—seminal vesicle—prostate cancer	0.000437	0.0082	CbGeAlD
Imatinib—CA3—bone marrow—prostate cancer	0.000434	0.00815	CbGeAlD
Imatinib—NQO2—urethra—prostate cancer	0.000434	0.00814	CbGeAlD
Imatinib—PDGFRB—seminal vesicle—prostate cancer	0.000427	0.00801	CbGeAlD
Imatinib—SLC22A2—renal system—prostate cancer	0.000418	0.00785	CbGeAlD
Imatinib—ABL2—testis—prostate cancer	0.000411	0.00771	CbGeAlD
Imatinib—CA12—renal system—prostate cancer	0.000406	0.00763	CbGeAlD
Imatinib—LCK—bone marrow—prostate cancer	0.000403	0.00757	CbGeAlD
Imatinib—PIP4K2C—testis—prostate cancer	0.000389	0.00729	CbGeAlD
Imatinib—CSF1R—urethra—prostate cancer	0.000381	0.00715	CbGeAlD
Imatinib—ABL1—seminal vesicle—prostate cancer	0.00038	0.00714	CbGeAlD
Imatinib—KIT—epithelium—prostate cancer	0.00038	0.00713	CbGeAlD
Imatinib—CA3—testis—prostate cancer	0.000371	0.00696	CbGeAlD
Imatinib—PDGFRB—epithelium—prostate cancer	0.000371	0.00696	CbGeAlD
Imatinib—CA9—testis—prostate cancer	0.000355	0.00667	CbGeAlD
Imatinib—SLC47A1—renal system—prostate cancer	0.000354	0.00665	CbGeAlD
Imatinib—KIT—renal system—prostate cancer	0.000352	0.00661	CbGeAlD
Imatinib—SLC47A1—urethra—prostate cancer	0.000348	0.00653	CbGeAlD
Imatinib—KIT—urethra—prostate cancer	0.000346	0.00649	CbGeAlD
Imatinib—LCK—testis—prostate cancer	0.000345	0.00647	CbGeAlD
Imatinib—PDGFRB—renal system—prostate cancer	0.000344	0.00646	CbGeAlD
Imatinib—ABL1—Levorphanol—Estrone—prostate cancer	0.000341	0.208	CbGdCrCtD
Imatinib—PDGFRB—urethra—prostate cancer	0.000338	0.00634	CbGeAlD
Imatinib—NQO2—bone marrow—prostate cancer	0.000334	0.00627	CbGeAlD
Imatinib—CA1—renal system—prostate cancer	0.000322	0.00604	CbGeAlD
Imatinib—Ponatinib—SRC—prostate cancer	0.000314	0.0805	CrCbGaD
Imatinib—ABL1—renal system—prostate cancer	0.000306	0.00575	CbGeAlD
Imatinib—CA2—prostate gland—prostate cancer	0.000306	0.00575	CbGeAlD
Imatinib—ABL1—urethra—prostate cancer	0.000301	0.00565	CbGeAlD
Imatinib—ABL2—lymph node—prostate cancer	0.000298	0.00559	CbGeAlD
Imatinib—SLC22A1—renal system—prostate cancer	0.000295	0.00555	CbGeAlD
Imatinib—Ponatinib—KDR—prostate cancer	0.000295	0.0756	CrCbGaD
Imatinib—CSF1R—bone marrow—prostate cancer	0.000293	0.0055	CbGeAlD
Imatinib—Nilotinib—PDGFRB—prostate cancer	0.000288	0.0736	CrCbGaD
Imatinib—NQO2—testis—prostate cancer	0.000285	0.00536	CbGeAlD
Imatinib—PDGFRA—testis—prostate cancer	0.000285	0.00534	CbGeAlD
Imatinib—ABCG2—prostate gland—prostate cancer	0.000284	0.00532	CbGeAlD
Imatinib—PIP4K2C—lymph node—prostate cancer	0.000282	0.00529	CbGeAlD
Imatinib—CA3—lymph node—prostate cancer	0.000269	0.00505	CbGeAlD
Imatinib—KIT—bone marrow—prostate cancer	0.000266	0.005	CbGeAlD
Imatinib—CYP3A5—prostate gland—prostate cancer	0.000263	0.00494	CbGeAlD
Imatinib—PDGFRB—bone marrow—prostate cancer	0.00026	0.00488	CbGeAlD
Imatinib—CA2—seminal vesicle—prostate cancer	0.000259	0.00486	CbGeAlD
Imatinib—ABL1—Levorphanol—Estradiol—prostate cancer	0.000258	0.158	CbGdCrCtD
Imatinib—CSF1R—testis—prostate cancer	0.000251	0.0047	CbGeAlD
Imatinib—LCK—lymph node—prostate cancer	0.00025	0.00469	CbGeAlD
Imatinib—ORM1—bone marrow—prostate cancer	0.000244	0.00458	CbGeAlD
Imatinib—CA1—bone marrow—prostate cancer	0.000243	0.00457	CbGeAlD
Imatinib—ABCG2—seminal vesicle—prostate cancer	0.00024	0.0045	CbGeAlD
Imatinib—PTGS1—prostate gland—prostate cancer	0.000236	0.00444	CbGeAlD
Imatinib—ABL1—bone marrow—prostate cancer	0.000232	0.00435	CbGeAlD
Imatinib—SLC47A1—testis—prostate cancer	0.000229	0.0043	CbGeAlD
Imatinib—KIT—testis—prostate cancer	0.000228	0.00427	CbGeAlD
Imatinib—CA2—epithelium—prostate cancer	0.000225	0.00422	CbGeAlD
Imatinib—PDGFRB—testis—prostate cancer	0.000222	0.00417	CbGeAlD
Imatinib—CA2—renal system—prostate cancer	0.000209	0.00392	CbGeAlD
Imatinib—NQO2—lymph node—prostate cancer	0.000207	0.00388	CbGeAlD
Imatinib—PDGFRA—lymph node—prostate cancer	0.000206	0.00387	CbGeAlD
Imatinib—PTGS1—seminal vesicle—prostate cancer	0.0002	0.00376	CbGeAlD
Imatinib—ABL1—testis—prostate cancer	0.000198	0.00372	CbGeAlD
Imatinib—ABCG2—urethra—prostate cancer	0.00019	0.00356	CbGeAlD
Imatinib—CYP1A2—renal system—prostate cancer	0.000186	0.00349	CbGeAlD
Imatinib—ALB—testis—prostate cancer	0.000183	0.00343	CbGeAlD
Imatinib—CSF1R—lymph node—prostate cancer	0.000182	0.00341	CbGeAlD
Imatinib—ABL1—Doxorubicin—Epirubicin—prostate cancer	0.00018	0.11	CbGdCrCtD
Imatinib—ABL1—Daunorubicin—Epirubicin—prostate cancer	0.00018	0.11	CbGdCrCtD
Imatinib—ABL1—Idarubicin—Epirubicin—prostate cancer	0.00018	0.11	CbGdCrCtD
Imatinib—CYP3A5—renal system—prostate cancer	0.000179	0.00337	CbGeAlD
Imatinib—Ponatinib—CYP3A5—prostate cancer	0.000178	0.0456	CrCbGaD
Imatinib—PTGS1—epithelium—prostate cancer	0.000174	0.00326	CbGeAlD
Imatinib—ABL1—Epirubicin—Doxorubicin—prostate cancer	0.000166	0.102	CbGdCrCtD
Imatinib—ABL1—Idarubicin—Doxorubicin—prostate cancer	0.000166	0.102	CbGdCrCtD
Imatinib—ABL1—Daunorubicin—Doxorubicin—prostate cancer	0.000166	0.102	CbGdCrCtD
Imatinib—SLC47A1—lymph node—prostate cancer	0.000166	0.00311	CbGeAlD
Imatinib—KIT—lymph node—prostate cancer	0.000165	0.0031	CbGeAlD
Imatinib—PTGS1—renal system—prostate cancer	0.000161	0.00303	CbGeAlD
Imatinib—PDGFRB—lymph node—prostate cancer	0.000161	0.00302	CbGeAlD
Imatinib—CA2—bone marrow—prostate cancer	0.000158	0.00296	CbGeAlD
Imatinib—ORM1—lymph node—prostate cancer	0.000151	0.00284	CbGeAlD
Imatinib—CA1—lymph node—prostate cancer	0.000151	0.00283	CbGeAlD
Imatinib—ABCG2—bone marrow—prostate cancer	0.000146	0.00274	CbGeAlD
Imatinib—ABL1—lymph node—prostate cancer	0.000144	0.0027	CbGeAlD
Imatinib—ABCB1—prostate gland—prostate cancer	0.00014	0.00262	CbGeAlD
Imatinib—CA2—testis—prostate cancer	0.000135	0.00253	CbGeAlD
Imatinib—CYP3A4—renal system—prostate cancer	0.000135	0.00253	CbGeAlD
Imatinib—ALB—lymph node—prostate cancer	0.000133	0.00249	CbGeAlD
Imatinib—CYP2D6—renal system—prostate cancer	0.000132	0.00249	CbGeAlD
Imatinib—ABCG2—testis—prostate cancer	0.000125	0.00235	CbGeAlD
Imatinib—ABCB1—seminal vesicle—prostate cancer	0.000118	0.00222	CbGeAlD
Imatinib—PTGS1—testis—prostate cancer	0.000104	0.00196	CbGeAlD
Imatinib—ABCB1—epithelium—prostate cancer	0.000103	0.00193	CbGeAlD
Imatinib—CA2—lymph node—prostate cancer	9.78e-05	0.00184	CbGeAlD
Imatinib—ABCB1—renal system—prostate cancer	9.53e-05	0.00179	CbGeAlD
Imatinib—ABCB1—urethra—prostate cancer	9.36e-05	0.00176	CbGeAlD
Imatinib—ABCG2—lymph node—prostate cancer	9.05e-05	0.0017	CbGeAlD
Imatinib—CYP2D6—testis—prostate cancer	8.56e-05	0.00161	CbGeAlD
Imatinib—Ponatinib—CYP3A4—prostate cancer	7.71e-05	0.0197	CrCbGaD
Imatinib—PTGS1—lymph node—prostate cancer	7.55e-05	0.00142	CbGeAlD
Imatinib—ABCB1—bone marrow—prostate cancer	7.21e-05	0.00135	CbGeAlD
Imatinib—ABCB1—testis—prostate cancer	6.16e-05	0.00116	CbGeAlD
Imatinib—Nilotinib—CYP3A4—prostate cancer	5.69e-05	0.0146	CrCbGaD
Imatinib—ABCB1—lymph node—prostate cancer	4.46e-05	0.000838	CbGeAlD
Imatinib—Unspecified disorder of skin and subcutaneous tissue—Prednisone—prostate cancer	1.68e-05	0.000118	CcSEcCtD
Imatinib—Dyspnoea—Docetaxel—prostate cancer	1.68e-05	0.000118	CcSEcCtD
Imatinib—Somnolence—Docetaxel—prostate cancer	1.68e-05	0.000117	CcSEcCtD
Imatinib—Discomfort—Prednisone—prostate cancer	1.68e-05	0.000117	CcSEcCtD
Imatinib—Eye disorder—Epirubicin—prostate cancer	1.67e-05	0.000117	CcSEcCtD
Imatinib—Hypersensitivity—Etoposide—prostate cancer	1.67e-05	0.000117	CcSEcCtD
Imatinib—Tinnitus—Epirubicin—prostate cancer	1.67e-05	0.000117	CcSEcCtD
Imatinib—Haemoglobin—Doxorubicin—prostate cancer	1.66e-05	0.000117	CcSEcCtD
Imatinib—Musculoskeletal discomfort—Capecitabine—prostate cancer	1.66e-05	0.000117	CcSEcCtD
Imatinib—Cardiac disorder—Epirubicin—prostate cancer	1.66e-05	0.000116	CcSEcCtD
Imatinib—Flushing—Epirubicin—prostate cancer	1.66e-05	0.000116	CcSEcCtD
Imatinib—Rhinitis—Doxorubicin—prostate cancer	1.66e-05	0.000116	CcSEcCtD
Imatinib—Dyspepsia—Docetaxel—prostate cancer	1.66e-05	0.000116	CcSEcCtD
Imatinib—Haemorrhage—Doxorubicin—prostate cancer	1.66e-05	0.000116	CcSEcCtD
Imatinib—Hepatitis—Doxorubicin—prostate cancer	1.66e-05	0.000116	CcSEcCtD
Imatinib—Insomnia—Capecitabine—prostate cancer	1.65e-05	0.000116	CcSEcCtD
Imatinib—Hypoaesthesia—Doxorubicin—prostate cancer	1.65e-05	0.000116	CcSEcCtD
Imatinib—Pharyngitis—Doxorubicin—prostate cancer	1.64e-05	0.000115	CcSEcCtD
Imatinib—Paraesthesia—Capecitabine—prostate cancer	1.64e-05	0.000115	CcSEcCtD
Imatinib—Decreased appetite—Docetaxel—prostate cancer	1.64e-05	0.000115	CcSEcCtD
Imatinib—Urinary tract disorder—Doxorubicin—prostate cancer	1.64e-05	0.000115	CcSEcCtD
Imatinib—Oedema peripheral—Doxorubicin—prostate cancer	1.63e-05	0.000114	CcSEcCtD
Imatinib—Gastrointestinal disorder—Docetaxel—prostate cancer	1.63e-05	0.000114	CcSEcCtD
Imatinib—Asthenia—Etoposide—prostate cancer	1.63e-05	0.000114	CcSEcCtD
Imatinib—Connective tissue disorder—Doxorubicin—prostate cancer	1.63e-05	0.000114	CcSEcCtD
Imatinib—Dyspnoea—Capecitabine—prostate cancer	1.63e-05	0.000114	CcSEcCtD
Imatinib—Oedema—Prednisone—prostate cancer	1.63e-05	0.000114	CcSEcCtD
Imatinib—Anaphylactic shock—Prednisone—prostate cancer	1.63e-05	0.000114	CcSEcCtD
Imatinib—Fatigue—Docetaxel—prostate cancer	1.63e-05	0.000114	CcSEcCtD
Imatinib—Angiopathy—Epirubicin—prostate cancer	1.62e-05	0.000114	CcSEcCtD
Imatinib—Urethral disorder—Doxorubicin—prostate cancer	1.62e-05	0.000114	CcSEcCtD
Imatinib—Nausea—Mitoxantrone—prostate cancer	1.62e-05	0.000114	CcSEcCtD
Imatinib—Immune system disorder—Epirubicin—prostate cancer	1.62e-05	0.000113	CcSEcCtD
Imatinib—Infection—Prednisone—prostate cancer	1.62e-05	0.000113	CcSEcCtD
Imatinib—Mediastinal disorder—Epirubicin—prostate cancer	1.61e-05	0.000113	CcSEcCtD
Imatinib—Pain—Docetaxel—prostate cancer	1.61e-05	0.000113	CcSEcCtD
Imatinib—Constipation—Docetaxel—prostate cancer	1.61e-05	0.000113	CcSEcCtD
Imatinib—Dyspepsia—Capecitabine—prostate cancer	1.61e-05	0.000113	CcSEcCtD
Imatinib—Chills—Epirubicin—prostate cancer	1.61e-05	0.000113	CcSEcCtD
Imatinib—Pruritus—Etoposide—prostate cancer	1.6e-05	0.000113	CcSEcCtD
Imatinib—Shock—Prednisone—prostate cancer	1.6e-05	0.000112	CcSEcCtD
Imatinib—Arrhythmia—Epirubicin—prostate cancer	1.6e-05	0.000112	CcSEcCtD
Imatinib—Nervous system disorder—Prednisone—prostate cancer	1.59e-05	0.000112	CcSEcCtD
Imatinib—Tachycardia—Prednisone—prostate cancer	1.59e-05	0.000111	CcSEcCtD
Imatinib—Decreased appetite—Capecitabine—prostate cancer	1.59e-05	0.000111	CcSEcCtD
Imatinib—Alopecia—Epirubicin—prostate cancer	1.58e-05	0.000111	CcSEcCtD
Imatinib—Skin disorder—Prednisone—prostate cancer	1.58e-05	0.000111	CcSEcCtD
Imatinib—Gastrointestinal disorder—Capecitabine—prostate cancer	1.58e-05	0.00011	CcSEcCtD
Imatinib—Fatigue—Capecitabine—prostate cancer	1.57e-05	0.00011	CcSEcCtD
Imatinib—Hyperhidrosis—Prednisone—prostate cancer	1.57e-05	0.00011	CcSEcCtD
Imatinib—Mental disorder—Epirubicin—prostate cancer	1.57e-05	0.00011	CcSEcCtD
Imatinib—Erythema multiforme—Doxorubicin—prostate cancer	1.57e-05	0.00011	CcSEcCtD
Imatinib—Pain—Capecitabine—prostate cancer	1.56e-05	0.000109	CcSEcCtD
Imatinib—Constipation—Capecitabine—prostate cancer	1.56e-05	0.000109	CcSEcCtD
Imatinib—Malnutrition—Epirubicin—prostate cancer	1.56e-05	0.000109	CcSEcCtD
Imatinib—Erythema—Epirubicin—prostate cancer	1.56e-05	0.000109	CcSEcCtD
Imatinib—Feeling abnormal—Docetaxel—prostate cancer	1.55e-05	0.000109	CcSEcCtD
Imatinib—Diarrhoea—Etoposide—prostate cancer	1.55e-05	0.000109	CcSEcCtD
Imatinib—Anorexia—Prednisone—prostate cancer	1.55e-05	0.000109	CcSEcCtD
Imatinib—Eye disorder—Doxorubicin—prostate cancer	1.55e-05	0.000109	CcSEcCtD
Imatinib—Tinnitus—Doxorubicin—prostate cancer	1.54e-05	0.000108	CcSEcCtD
Imatinib—Gastrointestinal pain—Docetaxel—prostate cancer	1.54e-05	0.000108	CcSEcCtD
Imatinib—Flushing—Doxorubicin—prostate cancer	1.54e-05	0.000108	CcSEcCtD
Imatinib—Cardiac disorder—Doxorubicin—prostate cancer	1.54e-05	0.000108	CcSEcCtD
Imatinib—Flatulence—Epirubicin—prostate cancer	1.54e-05	0.000108	CcSEcCtD
Imatinib—Dysgeusia—Epirubicin—prostate cancer	1.53e-05	0.000107	CcSEcCtD
Imatinib—Back pain—Epirubicin—prostate cancer	1.51e-05	0.000106	CcSEcCtD
Imatinib—Feeling abnormal—Capecitabine—prostate cancer	1.5e-05	0.000105	CcSEcCtD
Imatinib—Angiopathy—Doxorubicin—prostate cancer	1.5e-05	0.000105	CcSEcCtD
Imatinib—Dizziness—Etoposide—prostate cancer	1.5e-05	0.000105	CcSEcCtD
Imatinib—Muscle spasms—Epirubicin—prostate cancer	1.5e-05	0.000105	CcSEcCtD
Imatinib—Immune system disorder—Doxorubicin—prostate cancer	1.5e-05	0.000105	CcSEcCtD
Imatinib—Gastrointestinal pain—Capecitabine—prostate cancer	1.49e-05	0.000105	CcSEcCtD
Imatinib—Mediastinal disorder—Doxorubicin—prostate cancer	1.49e-05	0.000105	CcSEcCtD
Imatinib—Abdominal pain—Docetaxel—prostate cancer	1.49e-05	0.000104	CcSEcCtD
Imatinib—Body temperature increased—Docetaxel—prostate cancer	1.49e-05	0.000104	CcSEcCtD
Imatinib—Chills—Doxorubicin—prostate cancer	1.49e-05	0.000104	CcSEcCtD
Imatinib—Musculoskeletal discomfort—Prednisone—prostate cancer	1.48e-05	0.000104	CcSEcCtD
Imatinib—Arrhythmia—Doxorubicin—prostate cancer	1.48e-05	0.000104	CcSEcCtD
Imatinib—Insomnia—Prednisone—prostate cancer	1.47e-05	0.000103	CcSEcCtD
Imatinib—Vision blurred—Epirubicin—prostate cancer	1.47e-05	0.000103	CcSEcCtD
Imatinib—Alopecia—Doxorubicin—prostate cancer	1.46e-05	0.000103	CcSEcCtD
Imatinib—Paraesthesia—Prednisone—prostate cancer	1.46e-05	0.000102	CcSEcCtD
Imatinib—Mental disorder—Doxorubicin—prostate cancer	1.45e-05	0.000102	CcSEcCtD
Imatinib—Urticaria—Capecitabine—prostate cancer	1.45e-05	0.000102	CcSEcCtD
Imatinib—Ill-defined disorder—Epirubicin—prostate cancer	1.45e-05	0.000101	CcSEcCtD
Imatinib—Body temperature increased—Capecitabine—prostate cancer	1.44e-05	0.000101	CcSEcCtD
Imatinib—Abdominal pain—Capecitabine—prostate cancer	1.44e-05	0.000101	CcSEcCtD
Imatinib—Vomiting—Etoposide—prostate cancer	1.44e-05	0.000101	CcSEcCtD
Imatinib—Erythema—Doxorubicin—prostate cancer	1.44e-05	0.000101	CcSEcCtD
Imatinib—Malnutrition—Doxorubicin—prostate cancer	1.44e-05	0.000101	CcSEcCtD
Imatinib—Anaemia—Epirubicin—prostate cancer	1.44e-05	0.000101	CcSEcCtD
Imatinib—Dyspepsia—Prednisone—prostate cancer	1.43e-05	0.0001	CcSEcCtD
Imatinib—Rash—Etoposide—prostate cancer	1.43e-05	0.0001	CcSEcCtD
Imatinib—Dermatitis—Etoposide—prostate cancer	1.43e-05	0.0001	CcSEcCtD
Imatinib—Headache—Etoposide—prostate cancer	1.42e-05	9.96e-05	CcSEcCtD
Imatinib—Flatulence—Doxorubicin—prostate cancer	1.42e-05	9.96e-05	CcSEcCtD
Imatinib—Decreased appetite—Prednisone—prostate cancer	1.41e-05	9.91e-05	CcSEcCtD
Imatinib—Dysgeusia—Doxorubicin—prostate cancer	1.41e-05	9.9e-05	CcSEcCtD
Imatinib—Malaise—Epirubicin—prostate cancer	1.4e-05	9.85e-05	CcSEcCtD
Imatinib—Fatigue—Prednisone—prostate cancer	1.4e-05	9.83e-05	CcSEcCtD
Imatinib—Vertigo—Epirubicin—prostate cancer	1.4e-05	9.81e-05	CcSEcCtD
Imatinib—Syncope—Epirubicin—prostate cancer	1.4e-05	9.8e-05	CcSEcCtD
Imatinib—Leukopenia—Epirubicin—prostate cancer	1.39e-05	9.78e-05	CcSEcCtD
Imatinib—Back pain—Doxorubicin—prostate cancer	1.39e-05	9.78e-05	CcSEcCtD
Imatinib—Constipation—Prednisone—prostate cancer	1.39e-05	9.75e-05	CcSEcCtD
Imatinib—Hypersensitivity—Docetaxel—prostate cancer	1.39e-05	9.74e-05	CcSEcCtD
Imatinib—Muscle spasms—Doxorubicin—prostate cancer	1.39e-05	9.72e-05	CcSEcCtD
Imatinib—Palpitations—Epirubicin—prostate cancer	1.38e-05	9.65e-05	CcSEcCtD
Imatinib—Loss of consciousness—Epirubicin—prostate cancer	1.37e-05	9.6e-05	CcSEcCtD
Imatinib—Cough—Epirubicin—prostate cancer	1.36e-05	9.53e-05	CcSEcCtD
Imatinib—Vision blurred—Doxorubicin—prostate cancer	1.36e-05	9.53e-05	CcSEcCtD
Imatinib—Asthenia—Docetaxel—prostate cancer	1.35e-05	9.48e-05	CcSEcCtD
Imatinib—Convulsion—Epirubicin—prostate cancer	1.35e-05	9.46e-05	CcSEcCtD
Imatinib—Nausea—Etoposide—prostate cancer	1.35e-05	9.45e-05	CcSEcCtD
Imatinib—Hypertension—Epirubicin—prostate cancer	1.35e-05	9.43e-05	CcSEcCtD
Imatinib—Hypersensitivity—Capecitabine—prostate cancer	1.34e-05	9.43e-05	CcSEcCtD
Imatinib—Feeling abnormal—Prednisone—prostate cancer	1.34e-05	9.39e-05	CcSEcCtD
Imatinib—Ill-defined disorder—Doxorubicin—prostate cancer	1.34e-05	9.38e-05	CcSEcCtD
Imatinib—Pruritus—Docetaxel—prostate cancer	1.33e-05	9.35e-05	CcSEcCtD
Imatinib—Anaemia—Doxorubicin—prostate cancer	1.33e-05	9.34e-05	CcSEcCtD
Imatinib—Gastrointestinal pain—Prednisone—prostate cancer	1.33e-05	9.32e-05	CcSEcCtD
Imatinib—Myalgia—Epirubicin—prostate cancer	1.33e-05	9.3e-05	CcSEcCtD
Imatinib—Chest pain—Epirubicin—prostate cancer	1.33e-05	9.3e-05	CcSEcCtD
Imatinib—Arthralgia—Epirubicin—prostate cancer	1.33e-05	9.3e-05	CcSEcCtD
Imatinib—Anxiety—Epirubicin—prostate cancer	1.32e-05	9.27e-05	CcSEcCtD
Imatinib—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—prostate cancer	1.32e-05	9.24e-05	CcSEcCtD
Imatinib—Discomfort—Epirubicin—prostate cancer	1.31e-05	9.19e-05	CcSEcCtD
Imatinib—Asthenia—Capecitabine—prostate cancer	1.31e-05	9.18e-05	CcSEcCtD
Imatinib—Malaise—Doxorubicin—prostate cancer	1.3e-05	9.11e-05	CcSEcCtD
Imatinib—Dry mouth—Epirubicin—prostate cancer	1.3e-05	9.09e-05	CcSEcCtD
Imatinib—Vertigo—Doxorubicin—prostate cancer	1.3e-05	9.08e-05	CcSEcCtD
Imatinib—Syncope—Doxorubicin—prostate cancer	1.29e-05	9.06e-05	CcSEcCtD
Imatinib—Urticaria—Prednisone—prostate cancer	1.29e-05	9.06e-05	CcSEcCtD
Imatinib—Pruritus—Capecitabine—prostate cancer	1.29e-05	9.05e-05	CcSEcCtD
Imatinib—Leukopenia—Doxorubicin—prostate cancer	1.29e-05	9.05e-05	CcSEcCtD
Imatinib—Diarrhoea—Docetaxel—prostate cancer	1.29e-05	9.04e-05	CcSEcCtD
Imatinib—Abdominal pain—Prednisone—prostate cancer	1.29e-05	9.01e-05	CcSEcCtD
Imatinib—Body temperature increased—Prednisone—prostate cancer	1.29e-05	9.01e-05	CcSEcCtD
Imatinib—Confusional state—Epirubicin—prostate cancer	1.28e-05	8.99e-05	CcSEcCtD
Imatinib—Palpitations—Doxorubicin—prostate cancer	1.27e-05	8.93e-05	CcSEcCtD
Imatinib—Anaphylactic shock—Epirubicin—prostate cancer	1.27e-05	8.91e-05	CcSEcCtD
Imatinib—Oedema—Epirubicin—prostate cancer	1.27e-05	8.91e-05	CcSEcCtD
Imatinib—Loss of consciousness—Doxorubicin—prostate cancer	1.27e-05	8.88e-05	CcSEcCtD
Imatinib—Infection—Epirubicin—prostate cancer	1.26e-05	8.86e-05	CcSEcCtD
Imatinib—Cough—Doxorubicin—prostate cancer	1.26e-05	8.82e-05	CcSEcCtD
Imatinib—Shock—Epirubicin—prostate cancer	1.25e-05	8.77e-05	CcSEcCtD
Imatinib—Convulsion—Doxorubicin—prostate cancer	1.25e-05	8.76e-05	CcSEcCtD
Imatinib—Diarrhoea—Capecitabine—prostate cancer	1.25e-05	8.76e-05	CcSEcCtD
Imatinib—Nervous system disorder—Epirubicin—prostate cancer	1.25e-05	8.74e-05	CcSEcCtD
Imatinib—Dizziness—Docetaxel—prostate cancer	1.25e-05	8.74e-05	CcSEcCtD
Imatinib—Thrombocytopenia—Epirubicin—prostate cancer	1.24e-05	8.73e-05	CcSEcCtD
Imatinib—Hypertension—Doxorubicin—prostate cancer	1.24e-05	8.73e-05	CcSEcCtD
Imatinib—Tachycardia—Epirubicin—prostate cancer	1.24e-05	8.7e-05	CcSEcCtD
Imatinib—Skin disorder—Epirubicin—prostate cancer	1.24e-05	8.66e-05	CcSEcCtD
Imatinib—Hyperhidrosis—Epirubicin—prostate cancer	1.23e-05	8.62e-05	CcSEcCtD
Imatinib—Arthralgia—Doxorubicin—prostate cancer	1.23e-05	8.6e-05	CcSEcCtD
Imatinib—Myalgia—Doxorubicin—prostate cancer	1.23e-05	8.6e-05	CcSEcCtD
Imatinib—Chest pain—Doxorubicin—prostate cancer	1.23e-05	8.6e-05	CcSEcCtD
Imatinib—Anxiety—Doxorubicin—prostate cancer	1.22e-05	8.57e-05	CcSEcCtD
Imatinib—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—prostate cancer	1.22e-05	8.55e-05	CcSEcCtD
Imatinib—Discomfort—Doxorubicin—prostate cancer	1.21e-05	8.5e-05	CcSEcCtD
Imatinib—Anorexia—Epirubicin—prostate cancer	1.21e-05	8.5e-05	CcSEcCtD
Imatinib—Dizziness—Capecitabine—prostate cancer	1.21e-05	8.46e-05	CcSEcCtD
Imatinib—Dry mouth—Doxorubicin—prostate cancer	1.2e-05	8.42e-05	CcSEcCtD
Imatinib—Vomiting—Docetaxel—prostate cancer	1.2e-05	8.4e-05	CcSEcCtD
Imatinib—Hypersensitivity—Prednisone—prostate cancer	1.2e-05	8.4e-05	CcSEcCtD
Imatinib—Rash—Docetaxel—prostate cancer	1.19e-05	8.33e-05	CcSEcCtD
Imatinib—Hypotension—Epirubicin—prostate cancer	1.19e-05	8.33e-05	CcSEcCtD
Imatinib—Dermatitis—Docetaxel—prostate cancer	1.19e-05	8.33e-05	CcSEcCtD
Imatinib—Confusional state—Doxorubicin—prostate cancer	1.19e-05	8.32e-05	CcSEcCtD
Imatinib—Headache—Docetaxel—prostate cancer	1.18e-05	8.28e-05	CcSEcCtD
Imatinib—Anaphylactic shock—Doxorubicin—prostate cancer	1.18e-05	8.25e-05	CcSEcCtD
Imatinib—Oedema—Doxorubicin—prostate cancer	1.18e-05	8.25e-05	CcSEcCtD
Imatinib—Infection—Doxorubicin—prostate cancer	1.17e-05	8.19e-05	CcSEcCtD
Imatinib—Asthenia—Prednisone—prostate cancer	1.17e-05	8.18e-05	CcSEcCtD
Imatinib—Vomiting—Capecitabine—prostate cancer	1.16e-05	8.14e-05	CcSEcCtD
Imatinib—Musculoskeletal discomfort—Epirubicin—prostate cancer	1.16e-05	8.12e-05	CcSEcCtD
Imatinib—Shock—Doxorubicin—prostate cancer	1.16e-05	8.12e-05	CcSEcCtD
Imatinib—Nervous system disorder—Doxorubicin—prostate cancer	1.15e-05	8.09e-05	CcSEcCtD
Imatinib—Thrombocytopenia—Doxorubicin—prostate cancer	1.15e-05	8.08e-05	CcSEcCtD
Imatinib—Rash—Capecitabine—prostate cancer	1.15e-05	8.07e-05	CcSEcCtD
Imatinib—Pruritus—Prednisone—prostate cancer	1.15e-05	8.06e-05	CcSEcCtD
Imatinib—Insomnia—Epirubicin—prostate cancer	1.15e-05	8.06e-05	CcSEcCtD
Imatinib—Dermatitis—Capecitabine—prostate cancer	1.15e-05	8.06e-05	CcSEcCtD
Imatinib—Tachycardia—Doxorubicin—prostate cancer	1.15e-05	8.05e-05	CcSEcCtD
Imatinib—Headache—Capecitabine—prostate cancer	1.14e-05	8.02e-05	CcSEcCtD
Imatinib—Skin disorder—Doxorubicin—prostate cancer	1.14e-05	8.01e-05	CcSEcCtD
Imatinib—Paraesthesia—Epirubicin—prostate cancer	1.14e-05	8.01e-05	CcSEcCtD
Imatinib—Hyperhidrosis—Doxorubicin—prostate cancer	1.14e-05	7.97e-05	CcSEcCtD
Imatinib—Dyspnoea—Epirubicin—prostate cancer	1.13e-05	7.95e-05	CcSEcCtD
Imatinib—Somnolence—Epirubicin—prostate cancer	1.13e-05	7.93e-05	CcSEcCtD
Imatinib—Anorexia—Doxorubicin—prostate cancer	1.12e-05	7.86e-05	CcSEcCtD
Imatinib—Nausea—Docetaxel—prostate cancer	1.12e-05	7.85e-05	CcSEcCtD
Imatinib—Dyspepsia—Epirubicin—prostate cancer	1.12e-05	7.85e-05	CcSEcCtD
Imatinib—Diarrhoea—Prednisone—prostate cancer	1.11e-05	7.8e-05	CcSEcCtD
Imatinib—Decreased appetite—Epirubicin—prostate cancer	1.11e-05	7.75e-05	CcSEcCtD
Imatinib—Hypotension—Doxorubicin—prostate cancer	1.1e-05	7.71e-05	CcSEcCtD
Imatinib—Gastrointestinal disorder—Epirubicin—prostate cancer	1.1e-05	7.7e-05	CcSEcCtD
Imatinib—Fatigue—Epirubicin—prostate cancer	1.1e-05	7.69e-05	CcSEcCtD
Imatinib—Pain—Epirubicin—prostate cancer	1.09e-05	7.62e-05	CcSEcCtD
Imatinib—Constipation—Epirubicin—prostate cancer	1.09e-05	7.62e-05	CcSEcCtD
Imatinib—Nausea—Capecitabine—prostate cancer	1.08e-05	7.6e-05	CcSEcCtD
Imatinib—Dizziness—Prednisone—prostate cancer	1.08e-05	7.54e-05	CcSEcCtD
Imatinib—Musculoskeletal discomfort—Doxorubicin—prostate cancer	1.07e-05	7.52e-05	CcSEcCtD
Imatinib—Insomnia—Doxorubicin—prostate cancer	1.06e-05	7.46e-05	CcSEcCtD
Imatinib—Paraesthesia—Doxorubicin—prostate cancer	1.06e-05	7.41e-05	CcSEcCtD
Imatinib—Dyspnoea—Doxorubicin—prostate cancer	1.05e-05	7.35e-05	CcSEcCtD
Imatinib—Feeling abnormal—Epirubicin—prostate cancer	1.05e-05	7.35e-05	CcSEcCtD
Imatinib—Somnolence—Doxorubicin—prostate cancer	1.05e-05	7.33e-05	CcSEcCtD
Imatinib—Gastrointestinal pain—Epirubicin—prostate cancer	1.04e-05	7.29e-05	CcSEcCtD
Imatinib—Dyspepsia—Doxorubicin—prostate cancer	1.04e-05	7.26e-05	CcSEcCtD
Imatinib—Vomiting—Prednisone—prostate cancer	1.03e-05	7.25e-05	CcSEcCtD
Imatinib—Rash—Prednisone—prostate cancer	1.03e-05	7.19e-05	CcSEcCtD
Imatinib—Dermatitis—Prednisone—prostate cancer	1.02e-05	7.18e-05	CcSEcCtD
Imatinib—Decreased appetite—Doxorubicin—prostate cancer	1.02e-05	7.17e-05	CcSEcCtD
Imatinib—Headache—Prednisone—prostate cancer	1.02e-05	7.14e-05	CcSEcCtD
Imatinib—Gastrointestinal disorder—Doxorubicin—prostate cancer	1.02e-05	7.12e-05	CcSEcCtD
Imatinib—Fatigue—Doxorubicin—prostate cancer	1.01e-05	7.11e-05	CcSEcCtD
Imatinib—Urticaria—Epirubicin—prostate cancer	1.01e-05	7.08e-05	CcSEcCtD
Imatinib—Pain—Doxorubicin—prostate cancer	1.01e-05	7.05e-05	CcSEcCtD
Imatinib—Constipation—Doxorubicin—prostate cancer	1.01e-05	7.05e-05	CcSEcCtD
Imatinib—Abdominal pain—Epirubicin—prostate cancer	1.01e-05	7.05e-05	CcSEcCtD
Imatinib—Body temperature increased—Epirubicin—prostate cancer	1.01e-05	7.05e-05	CcSEcCtD
Imatinib—Feeling abnormal—Doxorubicin—prostate cancer	9.69e-06	6.8e-05	CcSEcCtD
Imatinib—Nausea—Prednisone—prostate cancer	9.66e-06	6.77e-05	CcSEcCtD
Imatinib—Gastrointestinal pain—Doxorubicin—prostate cancer	9.62e-06	6.75e-05	CcSEcCtD
Imatinib—Hypersensitivity—Epirubicin—prostate cancer	9.37e-06	6.57e-05	CcSEcCtD
Imatinib—Urticaria—Doxorubicin—prostate cancer	9.35e-06	6.55e-05	CcSEcCtD
Imatinib—Abdominal pain—Doxorubicin—prostate cancer	9.3e-06	6.52e-05	CcSEcCtD
Imatinib—Body temperature increased—Doxorubicin—prostate cancer	9.3e-06	6.52e-05	CcSEcCtD
Imatinib—Asthenia—Epirubicin—prostate cancer	9.12e-06	6.4e-05	CcSEcCtD
Imatinib—Pruritus—Epirubicin—prostate cancer	9e-06	6.31e-05	CcSEcCtD
Imatinib—Diarrhoea—Epirubicin—prostate cancer	8.7e-06	6.1e-05	CcSEcCtD
Imatinib—Hypersensitivity—Doxorubicin—prostate cancer	8.67e-06	6.08e-05	CcSEcCtD
Imatinib—Asthenia—Doxorubicin—prostate cancer	8.44e-06	5.92e-05	CcSEcCtD
Imatinib—Dizziness—Epirubicin—prostate cancer	8.41e-06	5.9e-05	CcSEcCtD
Imatinib—Pruritus—Doxorubicin—prostate cancer	8.32e-06	5.84e-05	CcSEcCtD
Imatinib—Vomiting—Epirubicin—prostate cancer	8.08e-06	5.67e-05	CcSEcCtD
Imatinib—Diarrhoea—Doxorubicin—prostate cancer	8.05e-06	5.64e-05	CcSEcCtD
Imatinib—Rash—Epirubicin—prostate cancer	8.02e-06	5.62e-05	CcSEcCtD
Imatinib—Dermatitis—Epirubicin—prostate cancer	8.01e-06	5.62e-05	CcSEcCtD
Imatinib—Headache—Epirubicin—prostate cancer	7.97e-06	5.58e-05	CcSEcCtD
Imatinib—Dizziness—Doxorubicin—prostate cancer	7.78e-06	5.45e-05	CcSEcCtD
Imatinib—Nausea—Epirubicin—prostate cancer	7.55e-06	5.3e-05	CcSEcCtD
Imatinib—Vomiting—Doxorubicin—prostate cancer	7.48e-06	5.24e-05	CcSEcCtD
Imatinib—Rash—Doxorubicin—prostate cancer	7.42e-06	5.2e-05	CcSEcCtD
Imatinib—Dermatitis—Doxorubicin—prostate cancer	7.41e-06	5.2e-05	CcSEcCtD
Imatinib—Headache—Doxorubicin—prostate cancer	7.37e-06	5.17e-05	CcSEcCtD
Imatinib—Nausea—Doxorubicin—prostate cancer	6.99e-06	4.9e-05	CcSEcCtD
Imatinib—CYP2D6—Metabolism—TYMS—prostate cancer	6.34e-07	5.8e-06	CbGpPWpGaD
Imatinib—KIT—Signaling Pathways—MYC—prostate cancer	6.34e-07	5.8e-06	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism—NCOA1—prostate cancer	6.33e-07	5.79e-06	CbGpPWpGaD
Imatinib—KIT—Signaling Pathways—TGFB1—prostate cancer	6.32e-07	5.78e-06	CbGpPWpGaD
Imatinib—ABCB1—Metabolism—CYP1A1—prostate cancer	6.3e-07	5.76e-06	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism—TYMS—prostate cancer	6.28e-07	5.75e-06	CbGpPWpGaD
Imatinib—PDGFRB—Immune System—IL6—prostate cancer	6.28e-07	5.75e-06	CbGpPWpGaD
Imatinib—ALB—Hemostasis—TP53—prostate cancer	6.28e-07	5.74e-06	CbGpPWpGaD
Imatinib—KIT—Disease—AKT1—prostate cancer	6.27e-07	5.74e-06	CbGpPWpGaD
Imatinib—CYP2D6—Metabolism—GSTM1—prostate cancer	6.26e-07	5.73e-06	CbGpPWpGaD
Imatinib—ABCB1—Metabolism—ERCC2—prostate cancer	6.25e-07	5.72e-06	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism—CYP19A1—prostate cancer	6.24e-07	5.71e-06	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism—GSTM1—prostate cancer	6.21e-07	5.68e-06	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—MDM2—prostate cancer	6.21e-07	5.68e-06	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—EP300—prostate cancer	6.2e-07	5.67e-06	CbGpPWpGaD
Imatinib—KIT—Signaling Pathways—EGFR—prostate cancer	6.2e-07	5.67e-06	CbGpPWpGaD
Imatinib—LCK—Immune System—KRAS—prostate cancer	6.2e-07	5.67e-06	CbGpPWpGaD
Imatinib—LCK—Disease—MYC—prostate cancer	6.19e-07	5.66e-06	CbGpPWpGaD
Imatinib—CYP3A5—Metabolism—INS—prostate cancer	6.19e-07	5.66e-06	CbGpPWpGaD
Imatinib—ALB—Metabolism—CAV1—prostate cancer	6.18e-07	5.66e-06	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—AKR1C3—prostate cancer	6.18e-07	5.66e-06	CbGpPWpGaD
Imatinib—LCK—Disease—TGFB1—prostate cancer	6.18e-07	5.65e-06	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—PRKACB—prostate cancer	6.15e-07	5.63e-06	CbGpPWpGaD
Imatinib—CYP2D6—Metabolism—LPL—prostate cancer	6.15e-07	5.62e-06	CbGpPWpGaD
Imatinib—ABL1—Immune System—IL6—prostate cancer	6.12e-07	5.6e-06	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—ERBB2—prostate cancer	6.12e-07	5.6e-06	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism—LPL—prostate cancer	6.1e-07	5.58e-06	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—CYP17A1—prostate cancer	6.09e-07	5.57e-06	CbGpPWpGaD
Imatinib—CYP3A5—Metabolism—CREBBP—prostate cancer	6.06e-07	5.55e-06	CbGpPWpGaD
Imatinib—LCK—Disease—EGFR—prostate cancer	6.06e-07	5.54e-06	CbGpPWpGaD
Imatinib—ABCG2—Metabolism—PTEN—prostate cancer	6.04e-07	5.53e-06	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—PIK3CB—prostate cancer	6.04e-07	5.52e-06	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—SRC—prostate cancer	6.03e-07	5.52e-06	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism—RXRA—prostate cancer	6.02e-07	5.51e-06	CbGpPWpGaD
Imatinib—CYP2C19—Metabolism—MTHFR—prostate cancer	6.02e-07	5.51e-06	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—MYC—prostate cancer	6e-07	5.49e-06	CbGpPWpGaD
Imatinib—NTRK1—Signaling Pathways—AKT1—prostate cancer	6e-07	5.49e-06	CbGpPWpGaD
Imatinib—CYP3A7—Metabolism—PTEN—prostate cancer	5.99e-07	5.48e-06	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—TGFB1—prostate cancer	5.98e-07	5.47e-06	CbGpPWpGaD
Imatinib—SLC22A2—Metabolism—PTEN—prostate cancer	5.98e-07	5.47e-06	CbGpPWpGaD
Imatinib—PDGFRA—Disease—AKT1—prostate cancer	5.94e-07	5.43e-06	CbGpPWpGaD
Imatinib—CYP2D6—Metabolism—CYP1A1—prostate cancer	5.94e-07	5.43e-06	CbGpPWpGaD
Imatinib—ALB—Metabolism of lipids and lipoproteins—PIK3CA—prostate cancer	5.91e-07	5.41e-06	CbGpPWpGaD
Imatinib—CYP2C19—Metabolism—PPARA—prostate cancer	5.9e-07	5.4e-06	CbGpPWpGaD
Imatinib—CYP2D6—Metabolism—ERCC2—prostate cancer	5.89e-07	5.39e-06	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism—CYP1A1—prostate cancer	5.89e-07	5.39e-06	CbGpPWpGaD
Imatinib—ABCB1—Metabolism—MTHFR—prostate cancer	5.87e-07	5.37e-06	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—VEGFA—prostate cancer	5.87e-07	5.37e-06	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—EGFR—prostate cancer	5.87e-07	5.37e-06	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—prostate cancer	5.86e-07	5.36e-06	CbGpPWpGaD
Imatinib—KIT—Signaling Pathways—KRAS—prostate cancer	5.85e-07	5.36e-06	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism—ERCC2—prostate cancer	5.84e-07	5.34e-06	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—STAT3—prostate cancer	5.81e-07	5.32e-06	CbGpPWpGaD
Imatinib—PTGS1—Metabolism—PTEN—prostate cancer	5.81e-07	5.31e-06	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—CXCL8—prostate cancer	5.8e-07	5.31e-06	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism—COMT—prostate cancer	5.8e-07	5.31e-06	CbGpPWpGaD
Imatinib—PDGFRB—Disease—IL6—prostate cancer	5.8e-07	5.31e-06	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—NCOA2—prostate cancer	5.8e-07	5.31e-06	CbGpPWpGaD
Imatinib—PDGFRB—Immune System—AKT1—prostate cancer	5.8e-07	5.3e-06	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism—GSTP1—prostate cancer	5.77e-07	5.28e-06	CbGpPWpGaD
Imatinib—ABCG2—Metabolism—EP300—prostate cancer	5.76e-07	5.27e-06	CbGpPWpGaD
Imatinib—ABCB1—Metabolism—PPARA—prostate cancer	5.76e-07	5.27e-06	CbGpPWpGaD
Imatinib—CYP3A5—Metabolism—PIK3CD—prostate cancer	5.75e-07	5.26e-06	CbGpPWpGaD
Imatinib—LCK—Disease—KRAS—prostate cancer	5.72e-07	5.23e-06	CbGpPWpGaD
Imatinib—CYP3A7—Metabolism—EP300—prostate cancer	5.71e-07	5.23e-06	CbGpPWpGaD
Imatinib—SLC22A2—Metabolism—EP300—prostate cancer	5.71e-07	5.22e-06	CbGpPWpGaD
Imatinib—LCK—Immune System—PIK3CA—prostate cancer	5.69e-07	5.21e-06	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism—ITPR1—prostate cancer	5.68e-07	5.2e-06	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—CDKN1B—prostate cancer	5.67e-07	5.18e-06	CbGpPWpGaD
Imatinib—ABL1—Immune System—AKT1—prostate cancer	5.65e-07	5.17e-06	CbGpPWpGaD
Imatinib—ALB—Metabolism—PIK3CG—prostate cancer	5.63e-07	5.15e-06	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism of lipids and lipoproteins—EP300—prostate cancer	5.59e-07	5.11e-06	CbGpPWpGaD
Imatinib—SLC22A1—Metabolism—PTEN—prostate cancer	5.58e-07	5.1e-06	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—CASP3—prostate cancer	5.55e-07	5.08e-06	CbGpPWpGaD
Imatinib—CYP2C19—Metabolism—CAV1—prostate cancer	5.55e-07	5.08e-06	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—IL2—prostate cancer	5.55e-07	5.07e-06	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—KRAS—prostate cancer	5.54e-07	5.07e-06	CbGpPWpGaD
Imatinib—PTGS1—Metabolism—EP300—prostate cancer	5.54e-07	5.07e-06	CbGpPWpGaD
Imatinib—CYP2D6—Metabolism—MTHFR—prostate cancer	5.54e-07	5.06e-06	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—SLC5A5—prostate cancer	5.53e-07	5.06e-06	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism—MTHFR—prostate cancer	5.49e-07	5.02e-06	CbGpPWpGaD
Imatinib—CYP2D6—Metabolism—PPARA—prostate cancer	5.43e-07	4.97e-06	CbGpPWpGaD
Imatinib—CYP3A5—Metabolism—NOS3—prostate cancer	5.43e-07	4.97e-06	CbGpPWpGaD
Imatinib—ABCB1—Metabolism—CAV1—prostate cancer	5.42e-07	4.96e-06	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—CCND1—prostate cancer	5.41e-07	4.95e-06	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—CYP2E1—prostate cancer	5.4e-07	4.94e-06	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—MYC—prostate cancer	5.4e-07	4.94e-06	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—TGFB1—prostate cancer	5.39e-07	4.93e-06	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism—PPARA—prostate cancer	5.38e-07	4.93e-06	CbGpPWpGaD
Imatinib—KIT—Signaling Pathways—PIK3CA—prostate cancer	5.38e-07	4.92e-06	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism—TYMS—prostate cancer	5.37e-07	4.91e-06	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—CTNNB1—prostate cancer	5.35e-07	4.9e-06	CbGpPWpGaD
Imatinib—PDGFRB—Disease—AKT1—prostate cancer	5.35e-07	4.89e-06	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—NQO1—prostate cancer	5.34e-07	4.89e-06	CbGpPWpGaD
Imatinib—ALB—Metabolism—INS—prostate cancer	5.33e-07	4.88e-06	CbGpPWpGaD
Imatinib—SLC22A1—Metabolism—EP300—prostate cancer	5.32e-07	4.86e-06	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism—GSTM1—prostate cancer	5.31e-07	4.85e-06	CbGpPWpGaD
Imatinib—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CA—prostate cancer	5.3e-07	4.85e-06	CbGpPWpGaD
Imatinib—ALB—Hemostasis—AKT1—prostate cancer	5.3e-07	4.85e-06	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—EGFR—prostate cancer	5.28e-07	4.83e-06	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—TH—prostate cancer	5.27e-07	4.82e-06	CbGpPWpGaD
Imatinib—LCK—Disease—PIK3CA—prostate cancer	5.26e-07	4.81e-06	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—MMP9—prostate cancer	5.25e-07	4.8e-06	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—CDKN1A—prostate cancer	5.23e-07	4.78e-06	CbGpPWpGaD
Imatinib—ALB—Metabolism—CREBBP—prostate cancer	5.22e-07	4.78e-06	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—PTEN—prostate cancer	5.22e-07	4.77e-06	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism—LPL—prostate cancer	5.21e-07	4.76e-06	CbGpPWpGaD
Imatinib—KIT—Signaling Pathways—TP53—prostate cancer	5.2e-07	4.76e-06	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—CYP1B1—prostate cancer	5.12e-07	4.69e-06	CbGpPWpGaD
Imatinib—CYP2D6—Metabolism—CAV1—prostate cancer	5.11e-07	4.67e-06	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—PIK3CA—prostate cancer	5.09e-07	4.66e-06	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism—CAV1—prostate cancer	5.06e-07	4.63e-06	CbGpPWpGaD
Imatinib—CYP2C19—Metabolism—PIK3CG—prostate cancer	5.06e-07	4.63e-06	CbGpPWpGaD
Imatinib—LCK—Immune System—IL6—prostate cancer	5.04e-07	4.61e-06	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism—CYP1A1—prostate cancer	5.03e-07	4.6e-06	CbGpPWpGaD
Imatinib—CYP3A5—Metabolism—PIK3CB—prostate cancer	5.01e-07	4.59e-06	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—KRAS—prostate cancer	4.99e-07	4.57e-06	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism—ERCC2—prostate cancer	4.99e-07	4.56e-06	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—EP300—prostate cancer	4.98e-07	4.55e-06	CbGpPWpGaD
Imatinib—CYP3A5—Metabolism—PTGS2—prostate cancer	4.97e-07	4.54e-06	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—GGT1—prostate cancer	4.96e-07	4.54e-06	CbGpPWpGaD
Imatinib—ALB—Metabolism—PIK3CD—prostate cancer	4.95e-07	4.53e-06	CbGpPWpGaD
Imatinib—ABCB1—Metabolism—PIK3CG—prostate cancer	4.94e-07	4.52e-06	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—TP53—prostate cancer	4.93e-07	4.51e-06	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—NCOA1—prostate cancer	4.89e-07	4.47e-06	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—SRC—prostate cancer	4.84e-07	4.43e-06	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—prostate cancer	4.84e-07	4.42e-06	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—CYP19A1—prostate cancer	4.82e-07	4.41e-06	CbGpPWpGaD
Imatinib—CYP2C19—Metabolism—INS—prostate cancer	4.79e-07	4.38e-06	CbGpPWpGaD
Imatinib—KIT—Signaling Pathways—IL6—prostate cancer	4.76e-07	4.36e-06	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—VEGFA—prostate cancer	4.71e-07	4.31e-06	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism—MTHFR—prostate cancer	4.69e-07	4.29e-06	CbGpPWpGaD
Imatinib—CYP2C19—Metabolism—CREBBP—prostate cancer	4.69e-07	4.29e-06	CbGpPWpGaD
Imatinib—ALB—Metabolism—NOS3—prostate cancer	4.68e-07	4.28e-06	CbGpPWpGaD
Imatinib—ABCB1—Metabolism—INS—prostate cancer	4.67e-07	4.27e-06	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—STAT3—prostate cancer	4.67e-07	4.27e-06	CbGpPWpGaD
Imatinib—LCK—Disease—IL6—prostate cancer	4.65e-07	4.26e-06	CbGpPWpGaD
Imatinib—CYP2D6—Metabolism—PIK3CG—prostate cancer	4.65e-07	4.25e-06	CbGpPWpGaD
Imatinib—LCK—Immune System—AKT1—prostate cancer	4.65e-07	4.25e-06	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—RXRA—prostate cancer	4.65e-07	4.25e-06	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism—PIK3CG—prostate cancer	4.61e-07	4.22e-06	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism—PPARA—prostate cancer	4.6e-07	4.21e-06	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—PIK3CA—prostate cancer	4.59e-07	4.2e-06	CbGpPWpGaD
Imatinib—ABCB1—Metabolism—CREBBP—prostate cancer	4.58e-07	4.19e-06	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—IL6—prostate cancer	4.51e-07	4.12e-06	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—COMT—prostate cancer	4.48e-07	4.1e-06	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—GSTP1—prostate cancer	4.46e-07	4.08e-06	CbGpPWpGaD
Imatinib—CYP2C19—Metabolism—PIK3CD—prostate cancer	4.45e-07	4.07e-06	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—TP53—prostate cancer	4.44e-07	4.06e-06	CbGpPWpGaD
Imatinib—CYP2D6—Metabolism—INS—prostate cancer	4.4e-07	4.03e-06	CbGpPWpGaD
Imatinib—KIT—Signaling Pathways—AKT1—prostate cancer	4.39e-07	4.02e-06	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—ITPR1—prostate cancer	4.39e-07	4.01e-06	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism—INS—prostate cancer	4.36e-07	3.99e-06	CbGpPWpGaD
Imatinib—ABCB1—Metabolism—PIK3CD—prostate cancer	4.34e-07	3.97e-06	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—MYC—prostate cancer	4.34e-07	3.97e-06	CbGpPWpGaD
Imatinib—CYP3A5—Metabolism—PTEN—prostate cancer	4.33e-07	3.96e-06	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism—CAV1—prostate cancer	4.33e-07	3.96e-06	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—TGFB1—prostate cancer	4.33e-07	3.96e-06	CbGpPWpGaD
Imatinib—ALB—Metabolism—PIK3CB—prostate cancer	4.32e-07	3.95e-06	CbGpPWpGaD
Imatinib—CYP2D6—Metabolism—CREBBP—prostate cancer	4.31e-07	3.94e-06	CbGpPWpGaD
Imatinib—LCK—Disease—AKT1—prostate cancer	4.29e-07	3.93e-06	CbGpPWpGaD
Imatinib—ALB—Metabolism—PTGS2—prostate cancer	4.28e-07	3.91e-06	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism—CREBBP—prostate cancer	4.28e-07	3.91e-06	CbGpPWpGaD
Imatinib—ABCG2—Metabolism—PIK3CA—prostate cancer	4.26e-07	3.9e-06	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—EGFR—prostate cancer	4.24e-07	3.88e-06	CbGpPWpGaD
Imatinib—CYP3A7—Metabolism—PIK3CA—prostate cancer	4.23e-07	3.87e-06	CbGpPWpGaD
Imatinib—SLC22A2—Metabolism—PIK3CA—prostate cancer	4.22e-07	3.86e-06	CbGpPWpGaD
Imatinib—CYP2C19—Metabolism—NOS3—prostate cancer	4.2e-07	3.84e-06	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—AKT1—prostate cancer	4.16e-07	3.8e-06	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—TYMS—prostate cancer	4.14e-07	3.79e-06	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—prostate cancer	4.13e-07	3.78e-06	CbGpPWpGaD
Imatinib—CYP3A5—Metabolism—EP300—prostate cancer	4.13e-07	3.78e-06	CbGpPWpGaD
Imatinib—ABCB1—Metabolism—NOS3—prostate cancer	4.1e-07	3.75e-06	CbGpPWpGaD
Imatinib—PTGS1—Metabolism—PIK3CA—prostate cancer	4.1e-07	3.75e-06	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—GSTM1—prostate cancer	4.1e-07	3.75e-06	CbGpPWpGaD
Imatinib—CYP2D6—Metabolism—PIK3CD—prostate cancer	4.09e-07	3.74e-06	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—IL6—prostate cancer	4.06e-07	3.72e-06	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism—PIK3CD—prostate cancer	4.05e-07	3.71e-06	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—LPL—prostate cancer	4.02e-07	3.68e-06	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—KRAS—prostate cancer	4.01e-07	3.67e-06	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism—PIK3CG—prostate cancer	3.94e-07	3.6e-06	CbGpPWpGaD
Imatinib—SLC22A1—Metabolism—PIK3CA—prostate cancer	3.93e-07	3.6e-06	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—CYP1A1—prostate cancer	3.88e-07	3.55e-06	CbGpPWpGaD
Imatinib—CYP2C19—Metabolism—PIK3CB—prostate cancer	3.87e-07	3.54e-06	CbGpPWpGaD
Imatinib—CYP2D6—Metabolism—NOS3—prostate cancer	3.86e-07	3.53e-06	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—ERCC2—prostate cancer	3.85e-07	3.52e-06	CbGpPWpGaD
Imatinib—CYP2C19—Metabolism—PTGS2—prostate cancer	3.84e-07	3.51e-06	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism—NOS3—prostate cancer	3.83e-07	3.5e-06	CbGpPWpGaD
Imatinib—ABCB1—Metabolism—PIK3CB—prostate cancer	3.78e-07	3.46e-06	CbGpPWpGaD
Imatinib—ABCB1—Metabolism—PTGS2—prostate cancer	3.75e-07	3.43e-06	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—AKT1—prostate cancer	3.75e-07	3.43e-06	CbGpPWpGaD
Imatinib—ALB—Metabolism—PTEN—prostate cancer	3.73e-07	3.41e-06	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism—INS—prostate cancer	3.73e-07	3.41e-06	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—PIK3CA—prostate cancer	3.68e-07	3.37e-06	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism—CREBBP—prostate cancer	3.65e-07	3.34e-06	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—MTHFR—prostate cancer	3.62e-07	3.31e-06	CbGpPWpGaD
Imatinib—CYP2D6—Metabolism—PIK3CB—prostate cancer	3.56e-07	3.26e-06	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—TP53—prostate cancer	3.56e-07	3.26e-06	CbGpPWpGaD
Imatinib—ALB—Metabolism—EP300—prostate cancer	3.56e-07	3.25e-06	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—PPARA—prostate cancer	3.55e-07	3.25e-06	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism—PIK3CB—prostate cancer	3.53e-07	3.23e-06	CbGpPWpGaD
Imatinib—CYP2D6—Metabolism—PTGS2—prostate cancer	3.53e-07	3.23e-06	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism—PTGS2—prostate cancer	3.5e-07	3.2e-06	CbGpPWpGaD
Imatinib—ABCG2—Metabolism—AKT1—prostate cancer	3.48e-07	3.19e-06	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism—PIK3CD—prostate cancer	3.46e-07	3.17e-06	CbGpPWpGaD
Imatinib—CYP3A7—Metabolism—AKT1—prostate cancer	3.45e-07	3.16e-06	CbGpPWpGaD
Imatinib—SLC22A2—Metabolism—AKT1—prostate cancer	3.45e-07	3.15e-06	CbGpPWpGaD
Imatinib—CYP2C19—Metabolism—PTEN—prostate cancer	3.35e-07	3.06e-06	CbGpPWpGaD
Imatinib—PTGS1—Metabolism—AKT1—prostate cancer	3.35e-07	3.06e-06	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—CAV1—prostate cancer	3.34e-07	3.05e-06	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism—NOS3—prostate cancer	3.27e-07	2.99e-06	CbGpPWpGaD
Imatinib—ABCB1—Metabolism—PTEN—prostate cancer	3.27e-07	2.99e-06	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—IL6—prostate cancer	3.26e-07	2.98e-06	CbGpPWpGaD
Imatinib—SLC22A1—Metabolism—AKT1—prostate cancer	3.21e-07	2.94e-06	CbGpPWpGaD
Imatinib—CYP2C19—Metabolism—EP300—prostate cancer	3.19e-07	2.92e-06	CbGpPWpGaD
Imatinib—ABCB1—Metabolism—EP300—prostate cancer	3.12e-07	2.85e-06	CbGpPWpGaD
Imatinib—CYP2D6—Metabolism—PTEN—prostate cancer	3.08e-07	2.82e-06	CbGpPWpGaD
Imatinib—CYP3A5—Metabolism—PIK3CA—prostate cancer	3.06e-07	2.8e-06	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism—PTEN—prostate cancer	3.05e-07	2.79e-06	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—PIK3CG—prostate cancer	3.04e-07	2.78e-06	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism—PIK3CB—prostate cancer	3.02e-07	2.76e-06	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—AKT1—prostate cancer	3.01e-07	2.75e-06	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism—PTGS2—prostate cancer	2.99e-07	2.74e-06	CbGpPWpGaD
Imatinib—CYP2D6—Metabolism—EP300—prostate cancer	2.94e-07	2.69e-06	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism—EP300—prostate cancer	2.91e-07	2.66e-06	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—INS—prostate cancer	2.88e-07	2.63e-06	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—CREBBP—prostate cancer	2.82e-07	2.58e-06	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—PIK3CD—prostate cancer	2.67e-07	2.45e-06	CbGpPWpGaD
Imatinib—ALB—Metabolism—PIK3CA—prostate cancer	2.63e-07	2.41e-06	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism—PTEN—prostate cancer	2.61e-07	2.39e-06	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—NOS3—prostate cancer	2.52e-07	2.31e-06	CbGpPWpGaD
Imatinib—CYP3A5—Metabolism—AKT1—prostate cancer	2.5e-07	2.28e-06	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism—EP300—prostate cancer	2.49e-07	2.28e-06	CbGpPWpGaD
Imatinib—CYP2C19—Metabolism—PIK3CA—prostate cancer	2.36e-07	2.16e-06	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—PIK3CB—prostate cancer	2.33e-07	2.13e-06	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—PTGS2—prostate cancer	2.31e-07	2.11e-06	CbGpPWpGaD
Imatinib—ABCB1—Metabolism—PIK3CA—prostate cancer	2.31e-07	2.11e-06	CbGpPWpGaD
Imatinib—CYP2D6—Metabolism—PIK3CA—prostate cancer	2.17e-07	1.99e-06	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism—PIK3CA—prostate cancer	2.15e-07	1.97e-06	CbGpPWpGaD
Imatinib—ALB—Metabolism—AKT1—prostate cancer	2.15e-07	1.97e-06	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—PTEN—prostate cancer	2.01e-07	1.84e-06	CbGpPWpGaD
Imatinib—CYP2C19—Metabolism—AKT1—prostate cancer	1.93e-07	1.77e-06	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—EP300—prostate cancer	1.92e-07	1.76e-06	CbGpPWpGaD
Imatinib—ABCB1—Metabolism—AKT1—prostate cancer	1.88e-07	1.72e-06	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism—PIK3CA—prostate cancer	1.84e-07	1.68e-06	CbGpPWpGaD
Imatinib—CYP2D6—Metabolism—AKT1—prostate cancer	1.77e-07	1.62e-06	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism—AKT1—prostate cancer	1.76e-07	1.61e-06	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism—AKT1—prostate cancer	1.5e-07	1.38e-06	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—PIK3CA—prostate cancer	1.42e-07	1.3e-06	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—AKT1—prostate cancer	1.16e-07	1.06e-06	CbGpPWpGaD
